Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.
Enviado por Luis Montaner el
Título | Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. |
Publication Type | Journal Article |
Year of Publication | 2004 |
Autores | Wysocka, M, Benoit, BM, Newton, S, Azzoni, L, Montaner, LJ, Rook, AH |
Journal | Blood |
Volume | 104 |
Issue | 13 |
Pagination | 4142-9 |
Date Published | 2004 Dec 15 |
ISSN | 0006-4971 |
Palabras clave | CD8-Positive T-Lymphocytes, Dendritic Cells, Dinucleoside Phosphates, Flow Cytometry, Humans, Immunity, Cellular, Interleukin-15, Killer Cells, Natural, Lymphoma, T-Cell, Cutaneous, Sezary Syndrome, T-Lymphocytes |
Abstract | Patients with advanced cutaneous T-cell lymphoma (CTCL) exhibit profound defects in cell-mediated immunity. Host immune functions appear to play an integral role in mediating disease-controlling responses in CTCL, therefore we investigated the effects of synthetic oligode-oxynucleotides with CpG motifs (CpG ODN), which have been recognized as immune stimulatory by virtue of activation of dendritic cells (DCs) following binding to Toll-like receptor (TLR) 9. Peripheral blood mononuclear cells (PBMCs) from patients with advanced CTCL (erythroderma with circulating malignant T cells) and healthy volunteers were cultured with either CpG-A or CpG-B ODN. Patients' PBMCs exhibited marked induction of interferon-alpha (IFN-alpha) release following culture with CpG-A. Similarly significant activation of NK cells and CD8 T cells occurred as assessed by up-modulation of CD69 expression and by natural killer lytic activity. Nevertheless, the PBMCs of patients exhibited blunted responses to CpG-A compared to healthy volunteers. In such cases, IL-15 was capable of producing levels of NK activation that were superior to CpG-A, while the combined effects of CpG-A plus IL-15 induced maximal activation of NK cells and further enhanced activation of CD8 T cells. These findings have important implications for the potential enhancement of antitumor immunity among patients with advanced CTCL. |
DOI | 10.1182/blood-2004-03-1190 |
Alternate Journal | Blood |
PubMed ID | 15328153 |
Grant List | CA 89442 / CA / NCI NIH HHS / United States CA00499 / CA / NCI NIH HHS / United States CA81022 / CA / NCI NIH HHS / United States |